Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa
Authors:
Open Access
- 1 March 1990
- journal article
- Published by American Society of Hematology in Blood
- Vol. 75 (5) , 1069-1073
Abstract
Infusing factor VIIa (FVIIa) has been reported to control bleeding in hemophilic patients with factor VIII (FVIII) inhibitors. This is difficult to attribute to an enhanced FVIIa/tissue factor (TF) activation of factor X, since in vitro studies suggest that infusion of FVIIa should neither increase substantially the rate of formation of FVIIa/TF complexes during hemostasis (Proc Natl Acad Sci USA 85:6687, 1988) nor bypass the dampening of TF-dependent coagulation by the extrinsic pathway inhibitor (EPI) (Blood 73:359, 1989). Partial thromboplastin times have also been reported to shorten after infusion of FVIIa. The experiments reported herein establish that shortening of partial thromboplastin times after adding FVIIa to hemophilic plasma in vitro stems from an FVIIa-catalyzed activation of factor X independent of possible trace contamination of reagents with TF. Experiments in purified systems confirmed that FVIIa can slowly activate factor X in a reaction mixture containing Ca2+ and phospholipid but no source of TF. The rate of activation was sufficient to account for the shortening of partial thromboplastin times observed. EPI, which turned off continuing FVIIa/TF activation of factor X, was unable to prevent continuing FVIIa/phospholipid activation of factor X. Because circulating plasma contains only a trace, if any, free FVIIa, such a reaction could never occur physiologically. However, infusing FVIIa creates a nonphysiologic circumstance in which a continuing slow FVIIa/phospholipid catalyzed activation of factor X could conceivably proceed in vivo unimpeded by EPI. Such a mechanism of factor X activation might compensate for an impaired factor IXa/FVIIIa/phospholipid activation of factor X during hemostatis, and therefore control bleeding in a hemophilic patient.Keywords
This publication has 8 references indexed in Scilit:
- Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.Proceedings of the National Academy of Sciences, 1989
- Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation.Proceedings of the National Academy of Sciences, 1988
- Characterization of anti-tissue factor antibody and its use in immunoaffinity purification of human tissue factorThrombosis Research, 1988
- Modifications of Extrinsic Pathway Inhibitor (EPI) and Factor Xa that Affect their Ability to Interact and to Inhibit Factor Vila/Tissue Factor: Evidence for a Two-Step Model of InhibitionThrombosis and Haemostasis, 1988
- Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation cofactorThrombosis Research, 1985
- Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.Journal of Clinical Investigation, 1983
- A Simplified Procedure for Purification of Human Prothrombin, Factor IX and Factor XPreparative Biochemistry, 1981
- Activated Prothrombin Concentrate for Patients with Factor VIII InhibitorsNew England Journal of Medicine, 1974